

**WHAT IS CLAIMED IS:**

1. A method for preventing the incidence of atrial fibrillation (AF) in a subject with chronic heart failure comprising the administration of a therapeutically effective amount of an ACE inhibitor.  
5
2. A method as defined in claim 1, wherein said chronic heart failure is a result of symptomatic or asymptomatic left ventricular systolic dysfunction.
- 10 3. A method as defined in claim 2, wherein said chronic heart failure is a result of symptomatic left ventricular systolic dysfunction.
4. A method as defined in claim 1, wherein said ACE inhibitor is selected from the group consisting of: enalapril (Vasotec®), captopril (Capoten®), lisinopril (Prinivil®, Zestril®), quinapril (Accupril®), ramipril (Altace®), trandolapril (Mavick®), perindopril (Coversyl®), and fosinopril (Monopril®).  
15
5. A method as defined in claim 4, wherein said ACE inhibitor enalapril is administered in an amount of about 5-20 mg/day, said ACE inhibitor captopril is administered in an amount of about 150 mg/day, said ACE inhibitor lisinopril is administered in an amount of about 20 mg/day, said ACE inhibitor quinapril is administered in an amount of about 40 mg/day, said ACE inhibitor ramipril is administered in an amount of about 10 mg/day, said ACE inhibitor trandolapril is administered in an amount of about 4 mg/day, said  
20 ACE inhibitor perindopril is administered in an amount of about 8 mg/day, and said ACE inhibitor fosinopril is administered in an amount of about 20 mg/day.  
25
6. A method as defined in claim 5, wherein said ACE inhibitor is enalapril.

7. A method for preventing the incidence of atrial fibrillation in a subject with chronic heart failure comprising the administration of a therapeutically effective amount of angiotensin II receptor antagonist.
- 5    8. A method as defined in claim 7, wherein said chronic heart failure is a result of symptomatic or asymptomatic left ventricular systolic dysfunction.
9. A method as defined in claim 8, wherein said chronic heart failure is a result of symptomatic left ventricular systolic dysfunction.
- 10    10. A method as defined in claim 9, wherein said angiotensin II receptor antagonist is selected from the group consisting of: losartan (Cozaar®), candesartan (Atacand®), irbesartan (Avapro®), telmisartan (Micardis®), valsartan (Diovan®) and eprosartan (Teveten®).
- 15    11. A method as defined in claim 10, wherein said angiotensin II receptor antagonist is administered in an amount of about 5-20 mg/day.
- 20    12. A method as defined in claim 11, wherein said angiotensin II receptor antagonist is losartan, valsartan or candesartan.